Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05428358

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Liver Metastases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasm Pancreatic Neoplasms

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aalborg University Hospital, Aalborg, Denmark

Loading trial locations.

About this study

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
  • No liver metastases on CT
  • At least 18 years old and able to provide informed consent
  • Expected pancreatic ductal adenocarcinoma based on CT scan

Exclusion criteria

  • Metastatic disease
  • Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
  • Comorbidity rendering major surgery unfeasible (inoperable)
  • No informed consent
  • Unable to undergo MRI (Kidney insufficiency (eGFR < 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
  • Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
  • MRI with liver-specific contrast performed during standard workup.

Treatment and study plan

Preoperative MRI

Diagnostic Test

Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection

Primary outcomes

  1. Change in treatment strategy

    Time frame: 1 week

    Change in treatment strategy from intended curative resection to other treatment based on MRI scan

Secondary outcomes

  1. Liver metastases

    Time frame: 1 week

    Proportion of patients who had liver metastases detected on MRI

  2. Surgery

    Time frame: 1 month

    Proportion of patients who made it to surgery/exploration

  3. Resection

    Time frame: 1 month

    Proportion of patients in each arm who had a pancreatic resection performed

  4. Intraoperatively detected liver metastases

    Time frame: 1 month

    Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI.

  5. Overall survival (1-year)

    Time frame: 1 year

    1-year overall survival.

  6. Overall survival (3-year)

    Time frame: 3 years

    3-year overall survival.

  7. Recurrence-free survival

    Time frame: 3 years

    Recurrence-free survival according to final treatment strategy.

  8. Healthcare costs

    Time frame: 3 years

    Healthcare costs in patients with change of treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Frank Mortensen, MD, DMSc

CONTACT

[email protected]

+45222517296

Jakob Kirkegård, MD, PhD

CONTACT

[email protected]

+4522900604

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Aalborg University Hospital
  • Rigshospitalet, Denmark

Registry information

Official study title

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.

Acronym: MAGIPAC

Important dates

Study start
2022
Primary completion
2027
Study completion
2028
First posted
Jun 23, 2022
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.